{"disease":{"id":"transition","name":"transition"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Transitional cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"durvalumab","indication_name":"Transitional cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imfinzi","generic_name":"durvalumab","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":"4900","mechanism":"Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"atezolizumab","indication_name":"Transitional cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecentriq","generic_name":"atezolizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"3700","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system."},{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Transitional Cell Bladder Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic transitional cell bladder carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"imfinzi","indication_name":"Transitional cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imfinzi","company_name":"University Medical Center Groningen","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05245773","title":"MORE-PC: A 30-day Automated SMS Program to Support Post-discharge Transitions of Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT04093245","title":"The LEARNING WISDOM Phase II Scale up Project","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Laval University","has_results":false},{"nct_id":"NCT03796923","title":"Models of Care in the Transition From the Secondary to the Primary Sector Among the Frailest Elderly","phase":"NA","overall_status":"COMPLETED","enrollment_count":3340,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT03683797","title":"Testing the Efficacy of a Post-discharge Call Program on the Rate of Readmission","phase":"NA","overall_status":"COMPLETED","enrollment_count":3267,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT06305130","title":"Prognostic Value of Performance Scores in Patients Undergoing Surgery for Upper Tract Urothelial Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":2515,"lead_sponsor_name":"Kaohsiung Medical University","has_results":false},{"nct_id":"NCT06924073","title":"Scale-up of an Evidence-based Adolescent Transition Package to Support Transitional Care Among Youth Living With HIV","phase":"NA","overall_status":"RECRUITING","enrollment_count":1920,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT03590002","title":"Evaluating the Effectiveness of an Electronic Medical Transfer Tool to Improve Communication During Transfers From ICU","phase":"NA","overall_status":"COMPLETED","enrollment_count":1751,"lead_sponsor_name":"Henry T. Stelfox, MD PhD","has_results":false},{"nct_id":"NCT00951496","title":"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1560,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00108745","title":"Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1157,"lead_sponsor_name":"GOG Foundation","has_results":true},{"nct_id":"NCT03574129","title":"Adolescent Transition To Adult Care for HIV-infected Adolescents in Kenya","phase":"NA","overall_status":"COMPLETED","enrollment_count":1095,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT00719303","title":"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1070,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":false},{"nct_id":"NCT05241951","title":"Preventing Medication-Related Problems in Care Transitions to Skilled Nursing Facilities","phase":"NA","overall_status":"COMPLETED","enrollment_count":1052,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT00565851","title":"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1052,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07396038","title":"INTRAOPERATIVE BLADDER INJURY ASSESSMENT IN TURBT USING BICEP","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Necmettin Erbakan University","has_results":false},{"nct_id":"NCT03509779","title":"Pronostic and Predictive Value of EMT in Localized Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"European Georges Pompidou Hospital","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT02323750","title":"TransitionCHF Systolic Dysfunction to Congestive Heart Failure Cohort Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Göttingen","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02450331","title":"A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":809,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05520983","title":"BEhavioral Health Stratified Treatment (BEST) Study for Youth With Intellectual and/or Developmental Disabilities (IDD)","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":780,"lead_sponsor_name":"University of Illinois at Chicago","has_results":false},{"nct_id":"NCT05182060","title":"Making Health Care Safer for Older Adults Receiving Skilled Home Health Care Services After Hospital Discharge","phase":"NA","overall_status":"COMPLETED","enrollment_count":761,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT03256877","title":"Detecting Transitional Cell Carcinoma From Haematuria","phase":"","overall_status":"COMPLETED","enrollment_count":750,"lead_sponsor_name":"Hull University Teaching Hospitals NHS Trust","has_results":false},{"nct_id":"NCT01167712","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":692,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03810534","title":"Connect-Home Clinical Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":654,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":true},{"nct_id":"NCT02502266","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":582,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04575935","title":"Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":580,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02446600","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":579,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06462001","title":"BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Nottingham University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT00989651","title":"Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":431,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03922529","title":"Modified Application of Cardiac Rehabilitation for Older Adults","phase":"NA","overall_status":"COMPLETED","enrollment_count":416,"lead_sponsor_name":"Daniel Forman, MD","has_results":true},{"nct_id":"NCT07001137","title":"Medication Reconciliation Process in Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":386,"lead_sponsor_name":"Centre Hospitalier de Saint-Denis","has_results":false},{"nct_id":"NCT02979353","title":"A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy","phase":"NA","overall_status":"COMPLETED","enrollment_count":372,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":true},{"nct_id":"NCT06982690","title":"Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":370,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03288545","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":348,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT07485114","title":"Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Daniel Keizman","has_results":false},{"nct_id":"NCT06911411","title":"PALLIATIVE ASSESSMENT COHORT IN THE GERIATRIC EMERGENCY SETTING","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"University Hospital Bispebjerg and Frederiksberg","has_results":false},{"nct_id":"NCT05232656","title":"PREventing Adverse Events Post-Discharge Through Proactive Identification, Multidisciplinary Communication, and Technology","phase":"NA","overall_status":"COMPLETED","enrollment_count":268,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06203509","title":"Improving Care Transitions for Medicaid Insured Individuals With Co-occurring Serious Mental Illness","phase":"NA","overall_status":"RECRUITING","enrollment_count":267,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT05405322","title":"Improving Care and Community Representation for Adolescents and Young Adults Living With HIV in West Africa","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":267,"lead_sponsor_name":"Institut de Recherche pour le Developpement","has_results":false},{"nct_id":"NCT05714605","title":"Implementation and Evaluation of A Health Innovation to Support Medicaid-Insured Individuals Following Hospitalization","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":267,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT03513159","title":"Improvement of Transition From Hospital to Home for Older Patients in Germany","phase":"NA","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT04333797","title":"Psychiatry of Transition in a World in Transition","phase":"NA","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"Queen Fabiola Children's University Hospital","has_results":false},{"nct_id":"NCT07256366","title":"How Reliable Are Routine Radiological Imaging Methods in Diagnosing Lumbosacral Transitional Vertebrae and Identifying the Pathological Disc Level?","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Marmara University","has_results":false},{"nct_id":"NCT06190288","title":"AdvantAGE: Implementation and Evaluation of an Interprofessional Tranistional Care Model for Frail Older Adults","phase":"NA","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Thekla Brunkert","has_results":false},{"nct_id":"NCT06244199","title":"Transition to Cardiac Rehabilitation (T2CR) to Address Barriers of Multimorbidity and Frailty","phase":"NA","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT03970174","title":"Care Transition Patient Experience Study With Electronic Tool","phase":"NA","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Trillium Health Partners","has_results":false},{"nct_id":"NCT05806606","title":"Effect and Cost Effectiveness of a Dyadic Empowerment-based Heart Failure Management Program for Self-care","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":232,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT03219333","title":"A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":219,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT05897125","title":"Telehealth Education Leveraging Electronic Transitions Of Care for COPD Patients","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":218,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT03312621","title":"Improving Health Care Transition for Youth With Special Needs","phase":"NA","overall_status":"COMPLETED","enrollment_count":209,"lead_sponsor_name":"Lisa Tuchman","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}